Protagonist Therapeutics Begins Phase 2b Trial of PTG-100 as Ulcerative Colitis Treatment

Protagonist Therapeutics Begins Phase 2b Trial of PTG-100 as Ulcerative Colitis Treatment
Protagonist Therapeutics has started a Phase 2b clinical trial to evaluate PTG-100, its lead candidate as a potential treatment for ulcerative colitis (UC). The multicenter, randomized, double-blind, placebo-controlled, parallel, adaptive two-stage trial (NCT02895100) will assess the effectiveness, safety and tolerability of PTG-100 in about 240 adults with moderate to severe UC. Researchers will randomly assign patients to

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *